RZN Nutraceuticals Continues Impressive String of Clinical Studies
MIAMI -- Continuing its tradition of validating product efficacy through rigorous clinical research, RZN Nutraceuticals released results of two randomized, placebo-controlled clinical trials showing its products - Arthri-Zen Relief(R) and Migra-Zen Relief PLUS(R) - provide natural, effective relief from arthritis and migraine pain.
Both trials were conducted by the independent Fenestra Research Labs. For the first trial, 75 chronic migraine headache sufferers were divided into three groups: placebo (daily), preventive (daily), and therapeutic (at migraine onset). Subjects taking placebo had a 2.2 percent reduction in headache frequency over the course of the 30-day trial. However, by the 24th day, everyone in the preventative group was migraine-free. In the therapeutic group, 69.1 percent of migraines were gone within 60 minutes of taking the product, and 85.4 percent within 90.
For the second trial, 75 subjects with extreme arthritis pain (daily at level 9 to 10 on a scale of 1-10) took Arthri-Zen Relief(R) or placebo. Patients taking placebo had no change in pain level during the 30-day study. Yet by day 7, nobody taking the Arthri-Zen Relief(R) was still at pain level 9-10. By day 14, every one of them was completely pain-free.
Arthri-Zen Relief(R) and Migra-Zen Relief PLUS(R) are made from a proprietary blend of extracts of juniper, goldenrod, dandelion, meadowsweet and willow bark, conjugated to fruit sugars and polysaccharides in a patent-pending delivery system that ensures their absorption.
Currently, RZN Nutraceuticals' products are marketed through national distributors and direct to natural accounts, international private label accounts, catalogue sales, practitioner offices, health clubs, and direct to consumer through the company's website, www.rznnutra.com. Future distribution channels include drug store and natural supplement chain outlets.
RZN has launched a direct marketing campaign and has plans for television and radio ads and a national public relations campaign starting in March. The company is conservatively projecting 2007 to net nearly $5 million in gross sales, which are expected to triple by 2008, and top $50 million by 2010. The company is actively looking for investors.
RZN Nutraceuticals is located in Miami, Florida. Arthri-Zen Relief(R) grew out of founder Mark Lubin's work to alleviate his own terrible arthritis pain. He later developed Migra-Zen Relief PLUS(R). For more information on Migra-Zen Relief PLUS(R) or any of the three Arthri-Zen Relief(R) formulations, please visit www.rznnutra.com, call Robert Hunt at 904-276-8324, or call Julie Nash of Christie Communications at 805-969-3744.
Contacts
RZN Nutraceuticals
Robert Hunt, 904-276-8324
robert@rznnutra.com
or
Christie Communications
Julie Nash, 805-969-3744
rajan@christiecomm.com
Both trials were conducted by the independent Fenestra Research Labs. For the first trial, 75 chronic migraine headache sufferers were divided into three groups: placebo (daily), preventive (daily), and therapeutic (at migraine onset). Subjects taking placebo had a 2.2 percent reduction in headache frequency over the course of the 30-day trial. However, by the 24th day, everyone in the preventative group was migraine-free. In the therapeutic group, 69.1 percent of migraines were gone within 60 minutes of taking the product, and 85.4 percent within 90.
For the second trial, 75 subjects with extreme arthritis pain (daily at level 9 to 10 on a scale of 1-10) took Arthri-Zen Relief(R) or placebo. Patients taking placebo had no change in pain level during the 30-day study. Yet by day 7, nobody taking the Arthri-Zen Relief(R) was still at pain level 9-10. By day 14, every one of them was completely pain-free.
Arthri-Zen Relief(R) and Migra-Zen Relief PLUS(R) are made from a proprietary blend of extracts of juniper, goldenrod, dandelion, meadowsweet and willow bark, conjugated to fruit sugars and polysaccharides in a patent-pending delivery system that ensures their absorption.
Currently, RZN Nutraceuticals' products are marketed through national distributors and direct to natural accounts, international private label accounts, catalogue sales, practitioner offices, health clubs, and direct to consumer through the company's website, www.rznnutra.com. Future distribution channels include drug store and natural supplement chain outlets.
RZN has launched a direct marketing campaign and has plans for television and radio ads and a national public relations campaign starting in March. The company is conservatively projecting 2007 to net nearly $5 million in gross sales, which are expected to triple by 2008, and top $50 million by 2010. The company is actively looking for investors.
RZN Nutraceuticals is located in Miami, Florida. Arthri-Zen Relief(R) grew out of founder Mark Lubin's work to alleviate his own terrible arthritis pain. He later developed Migra-Zen Relief PLUS(R). For more information on Migra-Zen Relief PLUS(R) or any of the three Arthri-Zen Relief(R) formulations, please visit www.rznnutra.com, call Robert Hunt at 904-276-8324, or call Julie Nash of Christie Communications at 805-969-3744.
Contacts
RZN Nutraceuticals
Robert Hunt, 904-276-8324
robert@rznnutra.com
or
Christie Communications
Julie Nash, 805-969-3744
rajan@christiecomm.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.